Log in

Relevant bibliographies by topics / Ulipristal acetate / Journal articles

To see the other types of publications on this topic, follow the link: Ulipristal acetate.

Journal articles on the topic 'Ulipristal acetate'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ulipristal acetate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

DURAN, Mehmet Nuri, Hacı Öztürk ŞAHİN, Nihal KILINÇ, and Bülent DEMİR. "The Effect of Ulipristal Acetate on Surgical Endometriosis Created in Rats." Artuklu International Journal of Health Sciences 2, no. 3 (2022): 15–19. http://dx.doi.org/10.58252/artukluder.1180091.

Full text

Abstract:

Objective: The effect of Ulipristal Acetate on endometriosis foci created in rats was investigated. Methods: The study was conducted with 12-week-old rats weighing approximately 280 grams. After creating an autologous endometriosis model, the group that did not receive ulipristal acetate negative was administered with oral saline daily, and the group given ulipristal acetate positive was administered with 0.5 mg/kg (0.125 mg/rat/day) orally for 4 weeks. Ectopic endometrial tissues were removed for histopathological and immunohistochemical evaluations. Staining was performed with Hematoxylin Eo

APA, Harvard, Vancouver, ISO, and other styles

2

Kavitha, Veladanda, and Rachamalla Madhuri. "Ulipristal Acetate Versus Leuprolide Acetate in Medical Management of Uterine Fibroids." Journal of Evolution of Medical and Dental Sciences 10, no. 43 (2021): 3701–6. http://dx.doi.org/10.14260/jemds/2021/749.

Full text

Abstract:

BACKGROUND We wanted to compare the effectiveness of the treatment and the adverse effects of ulipristal acetate and leuprolide acetate in the medical management of symptomatic uterine fibroids. METHODS This is a randomised controlled study conducted in the the Department of Obstetrics and Gynaecology in Chalmeda Anand Rao Institute of Medical Sciences from January 2019 to January 2020. 60 patients with symptomatic fibroids and excessive uterine bleeding were randomly divided. They were given daily therapy of ulipristal acetate 10 mg orally for 3 months or monthly injection leuprolide acetate

APA, Harvard, Vancouver, ISO, and other styles

3

McKeage, Kate, and Jamie D. Croxtall. "Ulipristal Acetate." Drugs 71, no. 7 (2011): 935–45. http://dx.doi.org/10.2165/11207410-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Croxtall, Jamie D. "Ulipristal Acetate." Drugs 72, no. 8 (2012): 1075–85. http://dx.doi.org/10.2165/11209400-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mozzanega, Bruno, Salvatore Gizzo, Stefania Di Gangi, Erich Cosmi, and Giovanni Battista Nardelli. "Ulipristal Acetate." Reproductive Sciences 21, no. 6 (2014): 678–85. http://dx.doi.org/10.1177/1933719113519178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lei, Rong Rong, Zuo Liang Sha, Liang Zhu, Li Bin Yang, and Yan Fei Wang. "Investigation on Thermal Decomposition Kinetics of Ulipristal Acetate (Form B)." Advanced Materials Research 791-793 (September 2013): 260–64. http://dx.doi.org/10.4028/www.scientific.net/amr.791-793.260.

Full text

Abstract:

Non-isothermal thermogravimetry analysis was applied to study the thermal decomposition kinetics of ulipristal acetate (form B). According to the experimental result, ulipristal acetate (form B) decomposed included three steps. Based on different kinetics function of corresponding thermal decomposition mechanisms and experimental data of ulipristal acetate (form B), decomposition mechanisms of three steps of ulipristal acetate (form B) were analyzed by differential method. According to fitting results of different mechanism functions, decomposition mechanisms of three steps of ulipristal aceta

APA, Harvard, Vancouver, ISO, and other styles

7

Shipika. "Ulipristal Acetate versus Placebo for Fibroid Treatment." International Journal of Toxicological and Pharmacological Research 13, no. 9 (2023): 206–11. https://doi.org/10.5281/zenodo.11081891.

Full text

Abstract:

<strong>Background: </strong>The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain. <strong>Methods: </strong>We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding]) and anemia (hemoglobin level of ≤10.2 g per deciliter) to receive treatment for up to 13 weeks with oral uli

APA, Harvard, Vancouver, ISO, and other styles

8

a, Shipika. "ULIPRISTAL ACETATE VERSUS PLACEBO FOR FIBROID TREATMENT." International Journal of Advanced Research 11, no. 07 (2023): 1348–54. http://dx.doi.org/10.21474/ijar01/17351.

Full text

Abstract:

Background: The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain. Methods: We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding]) and anemia (hemoglobin level of â‰¤10.2 g per deciliter) to receive treatment for up to 13 weeks with oral ulipristal acetate at a dose of 5 mg per day (96 wome

APA, Harvard, Vancouver, ISO, and other styles

9

a, Shipika. "ULIPRISTAL ACETATE VERSUS PLACEBO FOR FIBROID TREATMENT." International Journal of Advanced Research 11, no. 07 (2023): 1234–40. http://dx.doi.org/10.21474/ijar01/17342.

Full text

Abstract:

Background: The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain. Methods: We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding]) and anemia (hemoglobin level of â‰¤10.2 g per deciliter) to receive treatment for up to 13 weeks with oral ulipristal acetate at a dose of 5 mg per day (96 wome

APA, Harvard, Vancouver, ISO, and other styles

10

Costa, Ana R., Ana P. Carvalho, Diana R. Martins, et al. "Series of 55 pregnancies following ulipristal acetate treatment of symptomatic uterine fibroids." Journal of Endometriosis and Pelvic Pain Disorders 12, no. 3-4 (2020): 170–75. http://dx.doi.org/10.1177/2284026520932468.

Full text

Abstract:

Introduction: Treatment with ulipristal acetate effectively controls excessive bleeding due to uterine fibroids and reduces their size. Uterine fibroid size reduction is expected to improve the results of the myomectomy and the reproductive prospects of the patient. Methods: Retrospective and descriptive analysis of a series of 53 patients who achieved pregnancy after being treated for symptomatic uterine fibroids. The primary endpoints were pregnancy and birth outcomes in women with symptomatic uterine fibroids that conceived following at least one course of therapy with ulipristal acetate 5

APA, Harvard, Vancouver, ISO, and other styles

11

Behl, Pooja, Shalini Warman, Madhulima Saha, and Ojasvi Shanker. "Role of Ulipristal Acetate in Treatment of Fibroid: A Prospective Study." International Journal of Innovative Research in Medical Science 10, no. 04 (2025): 141–44. https://doi.org/10.23958/ijirms/vol10-i04/2050.

Full text

Abstract:

Background: Uterine fibroids are the most common benign tumours in women of reproductive age group which may present with heavy menstrual bleeding, dysmenorrhea, pelvic pressure and anaemia. Its management depends on the number, size and location of the ﬁbroids, patient’s age and desire to preserve fertility. Ulipristal acetate (UPA) is a selective progesterone receptor modulator which selectively inhibits the proliferation of uterine leiomyoma cells and induces their apoptosis. Objectives: The objective of the study was to evaluate the efficacy of ulipristal acetate in reducing the size of a

APA, Harvard, Vancouver, ISO, and other styles

12

Davies, Graham. "Ulipristal acetate emergency contraception." Journal of Family Planning and Reproductive Health Care 39, no. 1 (2013): 61.1–61. http://dx.doi.org/10.1136/jfprhc-2012-100519.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Giri Prasad Gorumutchu, Venkata Nadh Ratnakaram, and Kishore VNV. "Ulipristal acetate determination using MBTH." International Journal of Research in Pharmaceutical Sciences 10, no. 4 (2019): 3369–75. http://dx.doi.org/10.26452/ijrps.v10i4.1646.

Full text

Abstract:

A simple visible spectrophotometric method is proposed for the determination of ulipristal acetate present in bulk and tablet formulation. The currently proposed method is established based on MBTH oxidation by ferric ions to form an active coupling species (electrophile), followed by its coupling with the ulipristal in acidic medium to form high intensified green colored chromophore having lmax at 609 nm. Validated the method as per the current guidelines of ICH. Beer’s law was obeyed in the concentration range of 6.25 – 37.50 μg mL-1 with a high regression coefficient (r > 0.999). Reprodu

APA, Harvard, Vancouver, ISO, and other styles

14

Small, Benjamin, Charles E. F. Millard, Edwina P. Kisanga, et al. "The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor." Journal of Clinical Endocrinology & Metabolism 105, no. 3 (2019): 716–34. http://dx.doi.org/10.1210/clinem/dgz139.

Full text

Abstract:

Abstract Context The selective progesterone modulator ulipristal acetate (ulipristal) offers a much-needed therapeutic option for the clinical management of uterine fibroids. Although ulipristal initially passed safety evaluations in Europe, postmarketing analysis identified cases of hepatic injury and failure, leading to restrictions on the long-term use of ulipristal. One of the factors potentially contributing to significant side effects with the selective progesterone modulators is cross-reactivity with other steroid receptors. Objective To determine whether ulipristal can alter the activi

APA, Harvard, Vancouver, ISO, and other styles

15

Naresh, Neha, Poonam Mani, Lalita Yadav, and Nidhi Singh. "Role of selective progesterone receptor modulators in the treatment of symptomatic uterine fibroids." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 9, no. 7 (2020): 2703. http://dx.doi.org/10.18203/2320-1770.ijrcog20202583.

Full text

Abstract:

Background: Uterine leiomyomas are benign tumours of smooth muscle cells and fibrous tissue that develop within the wall of the uterus. Objective of this study was to compare efficacy and safety of Mifepristone and Ulipristal acetate in the treatment of symptomatic uterine fibroids.Methods: The present randomized comparative prospective study was conducted among 120 non-pregnant and non-lactating females of age 25-50 years with symptomatic fibroids reported in the department of obstetrics and gynecology, Chhatrapati Shivaji Subharti Hospital, Meerut, Uttar Pradesh for a duration of 2 years fro

APA, Harvard, Vancouver, ISO, and other styles

16

Horak, Petr, Michal Mara, Pavel Dundr, et al. "Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo." International Journal of Endocrinology 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/436174.

Full text

Abstract:

Aim. To determine if hormonal treatment induces apoptosis in uterine fibroids.Methods. Immunohistochemical examination of fibroid tissue, using avidin-biotin complex and cleaved caspase-3 antibody for detecting apoptosis, was performed in premenopausal women who underwent 12-week treatment with oral SPRM (6 patients with 5 mg and 5 patients with 10 mg of ulipristal acetate per day) or gonadoliberin agonist (GnRHa, 17 patients) and subsequent myomectomy or hysterectomy for symptomatic uterine fibroids. Ten patients with no presurgical hormonal treatment were used as controls.Results. Apoptosis

APA, Harvard, Vancouver, ISO, and other styles

17

Islam, Md Soriful, Sadia Afrin, Sara Isabel Jones, and James Segars. "Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility." Endocrine Reviews 41, no. 5 (2020): 643–94. http://dx.doi.org/10.1210/endrev/bnaa012.

Full text

Abstract:

Abstract Selective progesterone receptor modulators (SPRMs) are a new class of compounds developed to target the progesterone receptor (PR) with a mix of agonist and antagonist properties. These compounds have been introduced for the treatment of several gynecological conditions based on the critical role of progesterone in reproduction and reproductive tissues. In patients with uterine fibroids, mifepristone and ulipristal acetate have consistently demonstrated efficacy, and vilaprisan is currently under investigation, while studies of asoprisnil and telapristone were halted for safety concer

APA, Harvard, Vancouver, ISO, and other styles

18

Russo, J. A., and M. D. Creinin. "Ulipristal acetate for emergency contraception." Drugs of Today 46, no. 9 (2010): 655. http://dx.doi.org/10.1358/dot.2010.46.9.1516982.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Vitale, Salvatore Giovanni, Simone Ferrero, Salvatore Caruso, et al. "Ulipristal Acetate Before Hysteroscopic Myomectomy." Obstetrical & Gynecological Survey 75, no. 2 (2020): 127–35. http://dx.doi.org/10.1097/ogx.0000000000000764.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Snow, Sara E., Stephanie N. Melillo, and Courtney I. Jarvis. "Ulipristal Acetate for Emergency Contraception." Annals of Pharmacotherapy 45, no. 6 (2011): 780–86. http://dx.doi.org/10.1345/aph.1p704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Keenan, Jeffrey A. "Ulipristal Acetate: Contraceptive or Contragestive?" Annals of Pharmacotherapy 45, no. 6 (2011): 813–15. http://dx.doi.org/10.1345/aph.1q248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Piaggio, Gilda, and Helena von Hertzen. "Ulipristal acetate for emergency contraception?" Lancet 375, no. 9726 (2010): 1607–8. http://dx.doi.org/10.1016/s0140-6736(10)60699-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Page, Geert Herman, and Veerle Verhaeghe. "Ulipristal acetate for emergency contraception?" Lancet 375, no. 9726 (2010): 1608. http://dx.doi.org/10.1016/s0140-6736(10)60700-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Mine, Kadioglu, Cavusoglu Irem, Mehmet A. Osmanagaoglu, et al. "Ulipristal acetate exposure in pregnancy." Reproductive Toxicology 72 (September 2017): 218–19. http://dx.doi.org/10.1016/j.reprotox.2017.06.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Scattolon, S. A., A. Bullen, and N. A. Leyland. "Ulipristal Acetate and Pelvic Pain." Journal of Minimally Invasive Gynecology 24, no. 7 (2017): S186. http://dx.doi.org/10.1016/j.jmig.2017.08.559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Galliano, Daniela. "Ulipristal acetate in uterine fibroids." Fertility and Sterility 103, no. 2 (2015): 359–60. http://dx.doi.org/10.1016/j.fertnstert.2014.11.028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Kozachenko, A. V., Z. V. Revazova, L. V. Adamyan, T. A. Demura, and N. V. Zaytsev. "Hormonal assessment of patients of reproductive age with uterine myoma for surgical treatment." Medical Council, no. 13 (October 10, 2019): 29–35. http://dx.doi.org/10.21518/2079-701x-2019-13-29-35.

Full text

Abstract:

Aim: To assess the efficacy and safety of ulipristal acetate (UA) use in uterine myoma patients before surgical treatment. Material and methods: 78 patients of reproductive age with uterine bleeding and anemia, who underwent laparoscopic myomectomy, were included in the study. Patients were divided into two groups: the first group consisted of 43 women who received 5 mg of ulipristal acetate daily for 3 months before the operation and the second group consisted of 35 patients without ulipristal treatment. A comparative analysis was made between clinical laboratory data groups, pathomorphologic

APA, Harvard, Vancouver, ISO, and other styles

28

Patricia, Diaz Ortega, and Manuel García-Manero. "Influence of Ulipristal Acetate in 3D-PW-Doppler parameters of patients with uterine myomas: a prospective observational pilot study." Open Journal of Gynaecology and Obstetrics Research 2, no. 1 (2020): 11–18. https://doi.org/10.36811/ojgor.2020.110014.

Full text

Abstract:

<strong>Introduction:</strong> uterine fibroids are the most common benign tumors of the female genital tract. They associate a varied symptomatology, from the absence of symptoms to more disabling bleeding or pain [1,2]. There are multiple treatments directed against different targets such as ulipristal acetate which has proven effective in reducing the size of the fibroids and their symptoms [7]. Our preliminary study seeks to find the relationship between ulipristal acetate and angiogenesis of uterine fibroids, by measuring ultrasound vascularization of the fibroid throughout the treat

APA, Harvard, Vancouver, ISO, and other styles

29

Donnez, Jacques, Janusz Tomaszewski, Francisco Vázquez, et al. "Ulipristal Acetate Versus Leuprolide Acetate for Uterine Fibroids." Obstetrical & Gynecological Survey 68, no. 2 (2013): 99–100. http://dx.doi.org/10.1097/ogx.0b013e318280a140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Donnez, Jacques, Janusz Tomaszewski, Francisco Vázquez, et al. "Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids." New England Journal of Medicine 366, no. 5 (2012): 421–32. http://dx.doi.org/10.1056/nejmoa1103180.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Dungan, J. S. "Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids." Yearbook of Obstetrics, Gynecology and Women's Health 2012 (January 2012): 398–401. http://dx.doi.org/10.1016/j.yobg.2012.06.094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Wang, Peng, Yan Wang, Zili Suo, Yuanming Zhai, and Hui Li. "Cyclodextrin and its derivatives as effective excipients for amorphous ulipristal acetate systems." RSC Advances 12, no. 15 (2022): 9170–78. http://dx.doi.org/10.1039/d1ra09420c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sullivan, Jade L., and Marilyn N. Bulloch. "Ulipristal acetate: a new emergency contraceptive." Expert Review of Clinical Pharmacology 4, no. 4 (2011): 417–27. http://dx.doi.org/10.1586/ecp.11.21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Benlolo, Samantha, Jessica Papillon-Smith, and Ally Murji. "Ulipristal Acetate for Disseminated Peritoneal Leiomyomatosis." Obstetrics & Gynecology 133, no. 3 (2019): 434–36. http://dx.doi.org/10.1097/aog.0000000000003112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Hatfield, Joanna L. "Ulipristal Acetate for Symptomatic Uterine Leiomyomas." Obstetrics & Gynecology 133, no. 5 (2019): 867–68. http://dx.doi.org/10.1097/aog.0000000000003238.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lukes, Andrea, James A. Simon, Yiyong Fu, Vilma Sniukiene, and William Catherino. "Ulipristal Acetate Impact on Fibroid Volume." Obstetrics & Gynecology 131 (May 2018): 187S. http://dx.doi.org/10.1097/01.aog.0000533224.06520.23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Wilton, Jeanne M. "Ulipristal Acetate: The Newest Emergency Contraceptive." Nursing for Women's Health 16, no. 4 (2012): 331–35. http://dx.doi.org/10.1111/j.1751-486x.2012.01752.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Navarro Plazaola, Natalia, Marla Vega Chacana, and Raimundo Avilés Dorlhiac. "Effects of ulipristal acetate in patients with symptomatic uterine fibroids." Medwave 21, no. 04 (2021): e8162-e8162. http://dx.doi.org/10.5867/medwave.2021.04.8162.

Full text

Abstract:

Introducción Los miomas uterinos son una patología frecuente en ginecología, que tiene como desafío el enfrentamiento terapéutico. Existen nuevas terapias como el uso de acetato de ulipristal que podrían ayudar con el alivio sintomático y mejoría de la calidad de vida, además de la disminución del tamaño de los miomas uterinos. No obstante, existe controversia respecto a los efectos adversos, especialmente frente a la hepatotoxicidad. Métodos Realizamos una búsqueda en Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante el tamizaje de múltip

APA, Harvard, Vancouver, ISO, and other styles

39

А., Н. Григоренко. "Progesterone "against" progesterone. New links in the pathogenesis and future strategies in treatment of uterine fibroids." Reproductive Endocrinology, no. 43 (December 3, 2018): 77–81. https://doi.org/10.18370/2309-4117.2018.43.77-81.

Full text

Abstract:

Uterine myoma is a benign monoclonal solid tumor of the pelvis emanating from the smooth muscle tissue of the myometrium. Previously, it was considered that only hyperestrogens are the cause of the appearance and growth of fibromatosis. The high prevalence of uterine fibroids in the population forces the scientific world to explore the most subtle pathogenetic mechanisms in order to find an individual, personalized approach to its treatment. The last decade has been quite rich with new data on the pathogenesis of uterine fibroids, and yet, none of the theories of the initiation of the patholog

APA, Harvard, Vancouver, ISO, and other styles

40

Spinoso Cruz, Vicente, Marta Colechá Morales, Ligia Gil Melgosa, and Aida Revuelta Lopez. "Spontaneous Pregnancy following Treatment of Symptomatic Uterine Myomatosis with Ulipristal Acetate without Surgery." Obstetrics Gynecology and Reproductive Sciences 5, no. 3 (2021): 01–05. http://dx.doi.org/10.31579/2578-8965/059.

Full text

Abstract:

Uterine fibroids are the most frequent gynaecological benign tumors in women of reproductive age and can cause infertility. Their treatment may be medical, surgical or a combination of both, but they may compromise future fertility in patients in which their wish to conceive has not yet been fulfilled. In this report we present two patients with symptomatic uterine myomas and who wanted to preserve their fertility. Treatment with one or two 12-week courses of 5 mg of ulipristal acetate was prescribed. A decrease in the size of the fibroids was observed, along with adequate control of the sympt

APA, Harvard, Vancouver, ISO, and other styles

41

Cameron, Sharon T. "Emergency Contraception Options: Focus on Ulipristal Acetate." Clinical Medicine Insights: Women's Health 5 (January 2012): CMWH.S7642. http://dx.doi.org/10.4137/cmwh.s7642.

Full text

Abstract:

Ulipristal acetate (UPA) is a progesterone receptor modulator that is available for emergency contraception (EC) and can be taken up to 120 hours after unprotected intercourse. A meta-analysis of clinical trials comparing UPA with levonorgestrel (LNG) for EC, demonstrated that UPA has higher efficacy than LNG. This higher efficacy is supported by biomedical studies that have demonstrated that UPA is a more potent inhibitor of ovulation, being able to delay ovulation in the immediate preovulatory period, when LNG is no longer effective. A recent study that explored risk factors for failure of E

APA, Harvard, Vancouver, ISO, and other styles

42

Deshpande, Preeti Suhas, and Suhas Suresh Deshpande. "Effect of Ulipristal Acetate for Uterine Fibroids." Journal of Evolution of Medical and Dental Sciences 8, no. 49 (2019): 3675–78. http://dx.doi.org/10.14260/jemds/2019/795.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Martinez, Alan M., and Michael A. Thomas. "Ulipristal acetate as an emergency contraceptive agent." Expert Opinion on Pharmacotherapy 13, no. 13 (2012): 1937–42. http://dx.doi.org/10.1517/14656566.2012.705832.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Liu, James H., David Soper, Andrea Lukes, et al. "Ulipristal Acetate for Treatment of Uterine Leiomyomas." Obstetrics & Gynecology 132, no. 5 (2018): 1241–51. http://dx.doi.org/10.1097/aog.0000000000002942.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Glasier, Anna, and Erin Gainer. "Ulipristal acetate for emergency contraception? – Authors' reply." Lancet 375, no. 9726 (2010): 1608. http://dx.doi.org/10.1016/s0140-6736(10)60701-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Oscoz-Jaime, S., M. Larrea-García, M. J. Mitxelena-Eceiza, and N. Abián-Franco. "Progesterone Autoimmune Dermatitis Responding to Ulipristal Acetate." Actas Dermo-Sifiliográficas (English Edition) 110, no. 1 (2019): 78–81. http://dx.doi.org/10.1016/j.adengl.2018.11.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Singh, Sukhbir S., Devon Evans, Shannen McDonald, Mary Senterman, and Sarah Strickland. "Ulipristal Acetate Prior to Surgery for Endometriosis." Reproductive Sciences 27, no. 9 (2020): 1707–14. http://dx.doi.org/10.1007/s43032-020-00146-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Koyama, Atsuko, Laura Hagopian, and Judith Linden. "Emerging Options for Emergency Contraception." Clinical Medicine Insights: Reproductive Health 7 (January 2013): CMRH.S8145. http://dx.doi.org/10.4137/cmrh.s8145.

Full text

Abstract:

Emergency post-coital contraception (EC) is an effective method of preventing pregnancy when used appropriately. EC has been available since the 1970s, and its availability and use have become widespread. Options for EC are broad and include the copper intrauterine device (IUD) and emergency contraceptive pills such as levonorgestrel, ulipristal acetate, combined oral contraceptive pills (Yuzpe method), and less commonly, mifepristone. Some options are available over-the-counter, while others require provider prescription or placement. There are no absolute contraindications to the use of emer

APA, Harvard, Vancouver, ISO, and other styles

49

Khan, Farha. "Role of ulipristal acetate in management of uterine fibroid." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 13, no. 12 (2024): 3785–87. http://dx.doi.org/10.18203/2320-1770.ijrcog20243627.

Full text

Abstract:

Uterine fibroids are most common benign tumors in women of reproductive age group. Prevalence in rural population in India is 37.65% and 24% in urban population. Management depends on number, size, location of fibroid, patients age and fertility preservation. Ulipristal acetate is an orally active synthetic selective progesterone receptor modulator (SPRM). It competes at the progesterone binding site in a tissue specific manner. It decreases fibroid size and relieves symptoms. It inhibits cell proliferation and induces apoptosis leading to shrinkage of tumor. It is indicated for pre-operative

APA, Harvard, Vancouver, ISO, and other styles

50

Alcalde Dominguez, A., J. Rabasa Antonijuan, M. Cusidó Gimferrer, and M. Jiménez Ortuño. "Therapy with Ulipristal Acetate in a Hypertensive Patient." Case Reports in Medicine 2018 (November 1, 2018): 1–3. http://dx.doi.org/10.1155/2018/1091520.

Full text

Abstract:

Ulipristal acetate (UPA) is a medical therapy for patients with symptomatic uterine fibroids. The drug has shown efficacy in the control of heavy menstrual bleeding and, as a consequence, in anaemia improvement. We report the case of a hypertensive patient treated with two courses of UPA. In addition to its observed benefits on hypermenorrhea caused by uterine fibroids, no exacerbation of the underlying disease was observed. No adverse effects were observed, and blood pressure levels were well controlled throughout.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!